- Non-invasive glucose monitoring is still largely vapourware; a 2013 review by John L. Smith and a 2015 diagnostics paper conclude that no consumer-grade optical or spectroscopic device has yet met clinical accuracy requirements.  
- The only historical exception, Cygnus’s GlucoWatch, used reverse-iontophoresis and worked “reasonably well” according to ex-employees, but required $7.50 single-use sensors every 13 h, had a 25 % early-shut-off rate, and needed two devices for 24 h coverage—factors that killed the product commercially.  
- Finger-stick diagnostics beyond glucose and ketones are scarce; participants asked whether additional analytes could be added to the same strip format, noting that blood-ketone strips already exist at ~$3 each.  
- Abbott’s FreeStyle Libre is now available in the UK as a 14-day semi-implanted sensor that is factory-calibrated and eliminates finger-sticks, representing the closest current step toward long-term implantables.  
- Dexcom and similar CGMs remain semi-implanted because sensor reagents degrade; hackers extend individual sensors to 1–3 months with custom adhesives and firmware, but reliability varies widely.  
- A Tohoku University press release claims non-invasive blood-glucose measurement inside the mouth using infrared absorption; channel members are skeptical that this is more than new vapourware.  
- Discussion of an online biohacking platform concluded that “spaces” and new forums are irrelevant; what matters is cultivating skilled practitioners and providing them with money, equipment, and real-world experience.  
- CRISPR-Cpf1 (class-2 CRISPR-Cas system) was highlighted as a single-RNA-guided endonuclease alternative to Cas9, with a link to the 2015 Cell paper describing its mechanism.